RMTG’s Cellgenic launches MUSE cell product line in international markets

• Regenerative Medical Technology Group launched a MUSE cell product line via Cellgenic for selected international markets, subject to local rules.
• Expansion targets Latin America, the Middle East, Europe, Southeast Asia, positioning Cellgenic to widen its addressable physician base.
• Rollout follows an NK cell product launch on Aug. 24, signaling a repeatable pipeline that could support faster market entry.
• Management framed the cadence of differentiated launches as a competitive advantage, aiming to build operating leverage across its supply business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenerative Medical Technology Group Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608270701ACCESSWRNAPR_____1213091) on August 27, 2026, and is solely responsible for the information contained therein.